Continuous nicotinamide administration improves behavioral recovery and reduces lesion size following bilateral frontal controlled cortical impact injury

Cole Vonder Haar, Gail D. Anderson, Michael R. Hoane

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Previous research has demonstrated considerable preclinical efficacy of nicotinamide (NAM; vitamin B 3) in animal models of TBI with systemic dosing at 50 and 500mg/kg yielding improvements on sensory, motor, cognitive and histological measures. The current study aimed to utilize a more specific dosing paradigm in a clinically relevant delivery mechanism: continuously secreting subcutaneous pumps. A bilateral frontal controlled cortical impact (CCI) or sham surgery was performed and rats were treated with NAM (150mg/kgday) or saline (1ml/kg) pumps 30min after CCI, continuing until seven days post-CCI. Rats were given a loading dose of NAM (50mg/kg) or saline (1ml/kg) following pump implant. Rats received behavioral testing (bilateral tactile adhesive removal, locomotor placing task and Morris water maze) starting on day two post-CCI and were sacrificed at 31 days post-CCI and brains were stained to examine lesion size. NAM-treated rats had reductions in sensory, motor and cognitive behavioral deficits compared to vehicle-treated rats. Specifically, NAM-treated rats significantly improved on the bilateral tactile adhesive removal task, locomotor placing task and the reference memory paradigm of the Morris water maze. Lesion size was also significantly reduced in the NAM-treated group. The results from this study indicate that at the current dose, NAM produces beneficial effects on recovery from a bilateral frontal brain injury and that it may be a relevant compound to be explored in human studies.

Original languageEnglish (US)
Pages (from-to)311-317
Number of pages7
JournalBehavioural Brain Research
Volume224
Issue number2
DOIs
StatePublished - Oct 31 2011

Fingerprint

Niacinamide
Wounds and Injuries
Touch
Adhesives
Water
Brain Injuries
Animal Models
Brain
Research

Keywords

  • Rat
  • Recovery of function
  • Traumatic brain injury
  • Treatment
  • Vitamin B

ASJC Scopus subject areas

  • Behavioral Neuroscience

Cite this

Continuous nicotinamide administration improves behavioral recovery and reduces lesion size following bilateral frontal controlled cortical impact injury. / Vonder Haar, Cole; Anderson, Gail D.; Hoane, Michael R.

In: Behavioural Brain Research, Vol. 224, No. 2, 31.10.2011, p. 311-317.

Research output: Contribution to journalArticle

@article{fbe83dafb360412eaaad511e679ae4e1,
title = "Continuous nicotinamide administration improves behavioral recovery and reduces lesion size following bilateral frontal controlled cortical impact injury",
abstract = "Previous research has demonstrated considerable preclinical efficacy of nicotinamide (NAM; vitamin B 3) in animal models of TBI with systemic dosing at 50 and 500mg/kg yielding improvements on sensory, motor, cognitive and histological measures. The current study aimed to utilize a more specific dosing paradigm in a clinically relevant delivery mechanism: continuously secreting subcutaneous pumps. A bilateral frontal controlled cortical impact (CCI) or sham surgery was performed and rats were treated with NAM (150mg/kgday) or saline (1ml/kg) pumps 30min after CCI, continuing until seven days post-CCI. Rats were given a loading dose of NAM (50mg/kg) or saline (1ml/kg) following pump implant. Rats received behavioral testing (bilateral tactile adhesive removal, locomotor placing task and Morris water maze) starting on day two post-CCI and were sacrificed at 31 days post-CCI and brains were stained to examine lesion size. NAM-treated rats had reductions in sensory, motor and cognitive behavioral deficits compared to vehicle-treated rats. Specifically, NAM-treated rats significantly improved on the bilateral tactile adhesive removal task, locomotor placing task and the reference memory paradigm of the Morris water maze. Lesion size was also significantly reduced in the NAM-treated group. The results from this study indicate that at the current dose, NAM produces beneficial effects on recovery from a bilateral frontal brain injury and that it may be a relevant compound to be explored in human studies.",
keywords = "Rat, Recovery of function, Traumatic brain injury, Treatment, Vitamin B",
author = "{Vonder Haar}, Cole and Anderson, {Gail D.} and Hoane, {Michael R.}",
year = "2011",
month = "10",
day = "31",
doi = "10.1016/j.bbr.2011.06.009",
language = "English (US)",
volume = "224",
pages = "311--317",
journal = "Behavioural Brain Research",
issn = "0166-4328",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Continuous nicotinamide administration improves behavioral recovery and reduces lesion size following bilateral frontal controlled cortical impact injury

AU - Vonder Haar, Cole

AU - Anderson, Gail D.

AU - Hoane, Michael R.

PY - 2011/10/31

Y1 - 2011/10/31

N2 - Previous research has demonstrated considerable preclinical efficacy of nicotinamide (NAM; vitamin B 3) in animal models of TBI with systemic dosing at 50 and 500mg/kg yielding improvements on sensory, motor, cognitive and histological measures. The current study aimed to utilize a more specific dosing paradigm in a clinically relevant delivery mechanism: continuously secreting subcutaneous pumps. A bilateral frontal controlled cortical impact (CCI) or sham surgery was performed and rats were treated with NAM (150mg/kgday) or saline (1ml/kg) pumps 30min after CCI, continuing until seven days post-CCI. Rats were given a loading dose of NAM (50mg/kg) or saline (1ml/kg) following pump implant. Rats received behavioral testing (bilateral tactile adhesive removal, locomotor placing task and Morris water maze) starting on day two post-CCI and were sacrificed at 31 days post-CCI and brains were stained to examine lesion size. NAM-treated rats had reductions in sensory, motor and cognitive behavioral deficits compared to vehicle-treated rats. Specifically, NAM-treated rats significantly improved on the bilateral tactile adhesive removal task, locomotor placing task and the reference memory paradigm of the Morris water maze. Lesion size was also significantly reduced in the NAM-treated group. The results from this study indicate that at the current dose, NAM produces beneficial effects on recovery from a bilateral frontal brain injury and that it may be a relevant compound to be explored in human studies.

AB - Previous research has demonstrated considerable preclinical efficacy of nicotinamide (NAM; vitamin B 3) in animal models of TBI with systemic dosing at 50 and 500mg/kg yielding improvements on sensory, motor, cognitive and histological measures. The current study aimed to utilize a more specific dosing paradigm in a clinically relevant delivery mechanism: continuously secreting subcutaneous pumps. A bilateral frontal controlled cortical impact (CCI) or sham surgery was performed and rats were treated with NAM (150mg/kgday) or saline (1ml/kg) pumps 30min after CCI, continuing until seven days post-CCI. Rats were given a loading dose of NAM (50mg/kg) or saline (1ml/kg) following pump implant. Rats received behavioral testing (bilateral tactile adhesive removal, locomotor placing task and Morris water maze) starting on day two post-CCI and were sacrificed at 31 days post-CCI and brains were stained to examine lesion size. NAM-treated rats had reductions in sensory, motor and cognitive behavioral deficits compared to vehicle-treated rats. Specifically, NAM-treated rats significantly improved on the bilateral tactile adhesive removal task, locomotor placing task and the reference memory paradigm of the Morris water maze. Lesion size was also significantly reduced in the NAM-treated group. The results from this study indicate that at the current dose, NAM produces beneficial effects on recovery from a bilateral frontal brain injury and that it may be a relevant compound to be explored in human studies.

KW - Rat

KW - Recovery of function

KW - Traumatic brain injury

KW - Treatment

KW - Vitamin B

UR - http://www.scopus.com/inward/record.url?scp=80051784028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051784028&partnerID=8YFLogxK

U2 - 10.1016/j.bbr.2011.06.009

DO - 10.1016/j.bbr.2011.06.009

M3 - Article

C2 - 21704653

AN - SCOPUS:80051784028

VL - 224

SP - 311

EP - 317

JO - Behavioural Brain Research

JF - Behavioural Brain Research

SN - 0166-4328

IS - 2

ER -